PROLOR Biotech is developing proprietary versions of already-approved therapeutic proteins. The Company’s Carboxyl Terminal Peptide technology can be attached to an array of existing therapeutic proteins, stabilizing the therapy in the bloodstream and extending its lifespan without additional toxicity or loss of desired biological activity.
PROLOR products under development include Human Growth Hormone (“hGH”) for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone (a $3 billion market opportunity). PROLOR’s hGH could potentially be injected once a week or twice per month instead of daily. PROLOR’s hGH is scheduled for Phase III trials in 2013.
PROLOR’s GLP-1 / Glucagon dual receptor agonist for Diabetes Type II (a $2 billion market opportunity) could be injected once a week and may have a dramatically better weight-loss profile than current GLP-1 therapies.
PROLOR is also developing Factor VIIa and Factor IX for Hemophilia (a $2 billion market opportunity); Anti-Obesity Peptide Oxyntomodulin; Interferon ß and Erythropoietin; and Atherosclerosis and Rheumatoid Arthritis long-acting therapies.
PROLOR’s offices and research and development facilities are located in Israel in the Weizmann Science Park, Nes-Ziona.
Video Interview with Shai Novik, President of PROLOR Biotech
A Video Overview of PROLOR Biotech